SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-019305
Filing Date
2024-05-14
Accepted
2024-05-14 16:57:14
Documents
76
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1616414
2 ex31-1.htm EX-31.1 17138
3 ex31-2.htm EX-31.2 17137
4 ex32-1.htm EX-32.1 7512
5 ex32-2.htm EX-32.2 7297
  Complete submission text file 0001493152-24-019305.txt   8943814

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cldi-20240331.xsd EX-101.SCH 70441
7 XBRL CALCULATION FILE cldi-20240331_cal.xml EX-101.CAL 68782
8 XBRL DEFINITION FILE cldi-20240331_def.xml EX-101.DEF 364367
9 XBRL LABEL FILE cldi-20240331_lab.xml EX-101.LAB 554077
10 XBRL PRESENTATION FILE cldi-20240331_pre.xml EX-101.PRE 444252
79 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1426858
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

IRS No.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40789 | Film No.: 24945438
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)